Relyvrio, were on track for 10,000 patient level in the USA. They reached approx 1/3 of that.
The annual price was approx us$160,000 per patient.
Thats us$1.6b revenue annually.
Pharma industry colloquial description for a blockbuster, is greater than us$1b revenue. It was a throwaway line from Michael, trying to describe how big we could be without giving specifics, imho.
NZT gone but hasn't forgotten, page-43
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $92.46M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 18.5¢ | $177.2K | 929.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 499621 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 70000 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |